Germany’s Boehringer Ingelheim has made a move to expand its cancer pipeline via a takeover of T3 Pharma, a spinout from the University of Basel in Switzerland.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh